Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine.

Peeters CC, Rümke HC, Sundermann LC, Rouppe van der Voort EM, Meulenbelt J, Schuller M, Kuipers AJ, van der Ley P, Poolman JT.

Vaccine. 1996 Jul;14(10):1009-15.

PMID:
8873396
2.

Human B- and T-cell responses after immunization with a hexavalent PorA meningococcal outer membrane vesicle vaccine.

van der Voort ER, van Dijken H, Kuipers B, van der Biezen J, van der Ley P, Meylis J, Claassen I, Poolman J.

Infect Immun. 1997 Dec;65(12):5184-90.

3.

Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine.

van der Voort ER, van der Ley P, van der Biezen J, George S, Tunnela O, van Dijken H, Kuipers B, Poolman J.

Infect Immun. 1996 Jul;64(7):2745-51.

4.

Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age.

de Kleijn ED, de Groot R, Labadie J, Lafeber AB, van den Dobbelsteen G, van Alphen L, van Dijken H, Kuipers B, van Omme GW, Wala M, Juttmann R, Rümke HC.

Vaccine. 2000 Feb 14;18(15):1456-66.

PMID:
10618543
5.

Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine.

Martin SL, Borrow R, van der Ley P, Dawson M, Fox AJ, Cartwright KA.

Vaccine. 2000 May 22;18(23):2476-81.

PMID:
10775781
6.

PorA-specific differences in antibody avidity after vaccination with a hexavalent Men B outer membrane vesicle vaccine in toddlers and school children.

Vermont CL, Van Dijken HH, De Groot R, Van Alphen L, Van Den Dobbelsteen GP.

Vaccine. 2004 Aug 13;22(23-24):3008-13.

PMID:
15297049
7.

Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys.

Rouppe van der Voort E, Schuller M, Holst J, de Vries P, van der Ley P, van den Dobbelsteen G, Poolman J.

Vaccine. 2000 Jan 31;18(14):1334-43.

PMID:
10618530
8.

Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine.

Vermont CL, van Dijken HH, Kuipers AJ, van Limpt CJ, Keijzers WC, van der Ende A, de Groot R, van Alphen L, van den Dobbelsteen GP.

Infect Immun. 2003 Apr;71(4):1650-5.

9.

Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine.

de Kleijn E, van Eijndhoven L, Vermont C, Kuipers B, van Dijken H, Rümke H, de Groot R, van Alphen L, van den Dobbelsteen G.

Vaccine. 2001 Nov 12;20(3-4):352-8.

PMID:
11672897
10.

Heterologous prime-boost strategy to overcome weak immunogenicity of two serosubtypes in hexavalent Neisseria meningitidis outer membrane vesicle vaccine.

Luijkx T, van Dijken H, van Els C, van den Dobbelsteen G.

Vaccine. 2006 Mar 6;24(10):1569-77. Epub 2005 Oct 24.

PMID:
16298029
11.

Epitope specificity of murine and human bactericidal antibodies against PorA P1.7,16 induced with experimental meningococcal group B vaccines.

Rouppe van der Voort EM, Kuipers B, Brugghe HF, van Unen LM, Timmermans HA, Hoogerhout P, Poolman JT.

FEMS Immunol Med Microbiol. 1997 Mar;17(3):139-48.

12.
14.

Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins.

Cartwright K, Morris R, Rümke H, Fox A, Borrow R, Begg N, Richmond P, Poolman J.

Vaccine. 1999 Jun 4;17(20-21):2612-9.

PMID:
10418910
15.

Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school children.

Findlow J, Lowe A, Deane S, Balmer P, van den Dobbelsteen G, Dawson M, Andrews N, Borrow R.

Vaccine. 2005 Apr 8;23(20):2623-7.

PMID:
15780445
16.

Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form.

Luijkx TA, van Dijken H, Hamstra HJ, Kuipers B, van der Ley P, van Alphen L, van den Dobbelsteen G.

Infect Immun. 2003 Nov;71(11):6367-71.

17.

Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine.

Claassen I, Meylis J, van der Ley P, Peeters C, Brons H, Robert J, Borsboom D, van der Ark A, van Straaten I, Roholl P, Kuipers B, Poolman J.

Vaccine. 1996 Jul;14(10):1001-8.

PMID:
8873395
18.

Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents.

Boutriau D, Poolman J, Borrow R, Findlow J, Domingo JD, Puig-Barbera J, Baldó JM, Planelles V, Jubert A, Colomer J, Gil A, Levie K, Kervyn AD, Weynants V, Dominguez F, Barberá R, Sotolongo F.

Clin Vaccine Immunol. 2007 Jan;14(1):65-73. Epub 2006 Oct 25.

19.

A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.

Keiser PB, Biggs-Cicatelli S, Moran EE, Schmiel DH, Pinto VB, Burden RE, Miller LB, Moon JE, Bowden RA, Cummings JF, Zollinger WD.

Vaccine. 2011 Feb 4;29(7):1413-20. doi: 10.1016/j.vaccine.2010.12.039. Epub 2011 Jan 1.

PMID:
21199704
20.

Supplemental Content

Support Center